{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Lord+Caine&min-answer.dateOfAnswer=2019-05-15&min-ddpModified.=2019-09-09T17%3A10%3A09.518Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMemberPrinted.=Lord+Caine&min-answer.dateOfAnswer=2019-05-15&min-ddpModified.=2019-09-09T17%3A10%3A09.518Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Lord+Caine&min-answer.dateOfAnswer=2019-05-15&_metadata=all&min-ddpModified.=2019-09-09T17%3A10%3A09.518Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Lord+Caine&min-answer.dateOfAnswer=2019-05-15&_page=0&min-ddpModified.=2019-09-09T17%3A10%3A09.518Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Lord+Caine&min-answer.dateOfAnswer=2019-05-15&min-ddpModified.=2019-09-09T17%3A10%3A09.518Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMemberPrinted.=Lord+Caine&min-answer.dateOfAnswer=2019-05-15&min-ddpModified.=2019-09-09T17%3A10%3A09.518Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1364503", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1364503/answer", "answerText" : {"_value" : "

There is no specific prescribed service for treatment of fibrodysplasia ossificans progressiva (FOP). However, children with FOP are cared for by National Health Service paediatric rheumatologists and/or geneticists with input from other clinicians as required.<\/p>

New medicines and treatments for ultra-rare diseases such as FOP are considered via highly specialised technology (HST) evaluations by the National Institute for Health and Care Excellence (NICE). NICE is currently developing HST guidance on palovarotene for preventing heterotopic ossification associated with FOP.<\/p>

The UK Rare Diseases Framework, published in 2021, outlined four key priorities to improve the lives of those living with rare diseases, such as FOP, including improving access to specialist care, treatment and drugs. Action plans to improve access to care and treatment will be published by each of the four United Kingdom nations within two years. A copy of the Framework is attached.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"} } , "answeringMemberPrinted" : {"_value" : "Lord Kamall"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1364503/answer/attachment/1", "fileName" : {"_value" : "The UK Rare Diseases Framework.pdf"} , "title" : "The UK Rare Diseases Framework "} , "dateOfAnswer" : {"_value" : "2021-11-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL3514"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-11-11T13:34:39.907Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Fibrodysplasia Ossificans Progressiva: Health Services"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what specialist care and treatments are currently available through the NHS for people suffering from fibrodysplasia ossificans progressiva.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4581", "label" : {"_value" : "Biography information for Lord Caine"} } , "tablingMemberPrinted" : [{"_value" : "Lord Caine"} ], "uin" : "HL3513"} , {"_about" : "http://data.parliament.uk/resources/1364504", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1364504/answer", "answerText" : {"_value" : "

There is no specific prescribed service for treatment of fibrodysplasia ossificans progressiva (FOP). However, children with FOP are cared for by National Health Service paediatric rheumatologists and/or geneticists with input from other clinicians as required.<\/p>

New medicines and treatments for ultra-rare diseases such as FOP are considered via highly specialised technology (HST) evaluations by the National Institute for Health and Care Excellence (NICE). NICE is currently developing HST guidance on palovarotene for preventing heterotopic ossification associated with FOP.<\/p>

The UK Rare Diseases Framework, published in 2021, outlined four key priorities to improve the lives of those living with rare diseases, such as FOP, including improving access to specialist care, treatment and drugs. Action plans to improve access to care and treatment will be published by each of the four United Kingdom nations within two years. A copy of the Framework is attached.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"} } , "answeringMemberPrinted" : {"_value" : "Lord Kamall"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1364504/answer/attachment/1", "fileName" : {"_value" : "The UK Rare Diseases Framework.pdf"} , "title" : "The UK Rare Diseases Framework "} , "dateOfAnswer" : {"_value" : "2021-11-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "HL3513"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-11-11T13:34:39.957Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Fibrodysplasia Ossificans Progressiva: Health Services"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what plans they have, if any, to expand the provision of specialist NHS care and treatment for people suffering from fibrodysplasia ossificans progressiva.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4581", "label" : {"_value" : "Biography information for Lord Caine"} } , "tablingMemberPrinted" : [{"_value" : "Lord Caine"} ], "uin" : "HL3514"} , {"_about" : "http://data.parliament.uk/resources/1364505", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1364505/answer", "answerText" : {"_value" : "

The Department funds research into rare diseases such as fibrodysplasia ossificans progressiva (FOP) via the National Institute for Health Research (NIHR). In the past five years, the Department has provided funding to support eight studies into FOP through the NIHR. Within the NIHR, for all disease areas, the amount of funding depends on the volume and quality of scientific activity and the usual practice is not to ring-fence funds for particular topics.<\/p>

The UK Rare Diseases Framework, published in January 2021, outlined a vision for improving the lives of those with rare diseases, such as FOP, including a focus on pioneering research. Action plans setting out further details on this research will be published by each of the four United Kingdom nations within two years. A copy of the Framework is attached.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"} } , "answeringMemberPrinted" : {"_value" : "Lord Kamall"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1364505/answer/attachment/1", "fileName" : {"_value" : "The UK Rare Diseases Framework.pdf"} , "title" : "The UK Rare Diseases Framework"} , "dateOfAnswer" : {"_value" : "2021-11-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-11-11T13:33:43.847Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Fibrodysplasia Ossificans Progressiva: Research"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what plans they have, if any, to increase research funding in order to find more effective treatments and a cure for fibrodysplasia ossificans progressiva.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4581", "label" : {"_value" : "Biography information for Lord Caine"} } , "tablingMemberPrinted" : [{"_value" : "Lord Caine"} ], "uin" : "HL3515"} , {"_about" : "http://data.parliament.uk/resources/1364506", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1364506/answer", "answerText" : {"_value" : "

For patients with rare diseases such as fibrodysplasia ossificans progressiva, expert centres provide clinical guidance, support and advice to patients, their families and carers. The NHS Long Term Plan set out ambitions to improve the identification and support of unpaid carers. These ambitions include providing timely information and support for contingency planning; developing more integrated support systems within primary care; support for young carers; and work to ensure that carers from frequently excluded communities are engaged and enabled to use services.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4909", "label" : {"_value" : "Biography information for Lord Kamall"} } , "answeringMemberPrinted" : {"_value" : "Lord Kamall"} , "dateOfAnswer" : {"_value" : "2021-11-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-11-11T16:21:20.087Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-10-28", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Fibrodysplasia Ossificans Progressiva: Carers"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what support they are giving to families who are caring for family members  suffering from fibrodysplasia ossificans progressiva.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4581", "label" : {"_value" : "Biography information for Lord Caine"} } , "tablingMemberPrinted" : [{"_value" : "Lord Caine"} ], "uin" : "HL3516"} , {"_about" : "http://data.parliament.uk/resources/1303158", "AnsweringBody" : [{"_value" : "Treasury"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1303158/answer", "answerText" : {"_value" : "

The Stormont House Agreement between the UK Government and the Northern Ireland Executive agreed, in principle, for the power to set the rate of corporation tax in Northern Ireland on certain trading profits to be devolved to the Northern Ireland Assembly.<\/p>

It was agreed that the Executive would need to demonstrate that its finances were on a sustainable footing before devolution of this power could be undertaken, and that the Executive\u2019s block grant would need to be adjusted to reflect the corporation tax revenues foregone if the devolved power were exercised.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4689", "label" : {"_value" : "Biography information for Lord Agnew of Oulton"} } , "answeringMemberPrinted" : {"_value" : "Lord Agnew of Oulton"} , "dateOfAnswer" : {"_value" : "2021-03-31", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-31T13:22:09.64Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "14"} , "answeringDeptShortName" : {"_value" : "Treasury"} , "answeringDeptSortName" : {"_value" : "Treasury"} , "date" : {"_value" : "2021-03-16", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Corporation Tax: Northern Ireland"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what plans, if any, they have to devolve responsibility for corporation tax to the Northern Ireland Executive; what assessment they have made of the expected change in the level of revenue generated from corporation tax from any such transfer of responsibility; and, in particular, whether Her Majesty\u2019s Government would be able to offset any shortfall in revenue resulting from such a transfer of responsibility.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4581", "label" : {"_value" : "Biography information for Lord Caine"} } , "tablingMemberPrinted" : [{"_value" : "Lord Caine"} ], "uin" : "HL14260"} , {"_about" : "http://data.parliament.uk/resources/1290166", "AnsweringBody" : [{"_value" : "Northern Ireland Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1290166/answer", "answerText" : {"_value" : "

Good progress has been made in implementing the New Decade, New Approach deal, despite the huge challenge posed by the ongoing public health crisis.<\/p>

<\/p>

The UK Government has released over £555 million of the £2billion of funding agreed in the deal, and has delivered multiple commitments including appointing a Veterans Commissioner, launching the Shared History Fund as part of our programme to mark the centenary of Northern Ireland, and establishing the governance structures that underpin NDNA. On 24 February, the Secretary of State for Northern Ireland signed the Heads of Terms on the Derry/Londonderry and Strabane City Deal that will deliver tangible benefits to the North West and the whole of Northern Ireland.<\/p>

<\/p>

The UK Government is working to deliver the next tranche of our commitments, such as progressing legislation on the sustainability of the institutions and reforms to the Petition of Concern mechanism.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4169", "label" : {"_value" : "Biography information for Viscount Younger of Leckie"} } , "answeringMemberPrinted" : {"_value" : "Viscount Younger of Leckie"} , "dateOfAnswer" : {"_value" : "2021-03-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-09T16:17:11.647Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "21"} , "answeringDeptShortName" : {"_value" : "Northern Ireland"} , "answeringDeptSortName" : {"_value" : "Northern Ireland"} , "date" : {"_value" : "2021-02-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Northern Ireland Government"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government what outstanding legislative commitments they have for Northern Ireland in respect of the New Decade, New Approach Agreement 2020, published on 8 January 2020; and when they expect that these will be fulfilled.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4581", "label" : {"_value" : "Biography information for Lord Caine"} } , "tablingMemberPrinted" : [{"_value" : "Lord Caine"} ], "uin" : "HL13693"} , {"_about" : "http://data.parliament.uk/resources/1290167", "AnsweringBody" : [{"_value" : "Northern Ireland Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1290167/answer", "answerText" : {"_value" : "

The second report<\/a> on the operation of the Petition of Concern process was published on 12 January 2021. It recorded that no Petitions of Concern have been lodged in respect of any motion in the Assembly since the previous report<\/a> on 16 July 2020, and indeed, since the Executive was formed on 11 January 2020. The next report will deal with the period from 10 January 2021 to 11 July 2021.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4169", "label" : {"_value" : "Biography information for Viscount Younger of Leckie"} } , "answeringMemberPrinted" : {"_value" : "Viscount Younger of Leckie"} , "dateOfAnswer" : {"_value" : "2021-03-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-09T16:18:25.283Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "21"} , "answeringDeptShortName" : {"_value" : "Northern Ireland"} , "answeringDeptSortName" : {"_value" : "Northern Ireland"} , "date" : {"_value" : "2021-02-25", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Petition of Concern"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "To ask Her Majesty's Government how many reports on the operation of the Petition of Concern process in the Northern Ireland Assembly have been laid before both Houses of Parliament, in accordance with the commitment in Annex A of the New Decade, New Approach Agreement 2020, published on 8 January 2020, to lay such reports every six months.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4581", "label" : {"_value" : "Biography information for Lord Caine"} } , "tablingMemberPrinted" : [{"_value" : "Lord Caine"} ], "uin" : "HL13694"} , {"_about" : "http://data.parliament.uk/resources/1218107", "AnsweringBody" : [{"_value" : "Department for Digital, Culture, Media and Sport"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1218107/answer", "answerText" : {"_value" : "

DCMS continues to engage with the Music Venue Trust including through:<\/p>

<\/strong><\/p>